HIV/AIDS (2026 IMCU)

Only available as part of a package

Learning Objectives:

Understand "Undetectable = Untransmittable (U=U)" and its significance in eliminating HIV transmission risk.
Understand the importance of starting antiretroviral therapy (ART) early to achieve viral suppression, improve outcomes, and prevent transmission.
Learn to monitor HIV therapy with regular viral load testing for virologic suppression and CD4 count for immune status assessment. Identify the role of pre-exposure prophylaxis (PrEP) in preventing HIV infection and its e fectiveness when taken consistently. Determine which populations will most likely benefit from PrEP and how to implement it in clinical practice. Explore the use of doxycycline post-exposure prophylaxis (Doxy-PEP) to prevent bacterial STIs in high-risk individuals. Discuss its integration into HIV prevention strategies, particularly for patients on PrEP or living with HIV.

MarkAlain Déry, DO, MPH, FACOI (he/him/his)

Chief Innovation Officer

Access Health Louisiana

Dr. MarkAlain Déry is a distinguished infectious diseases physician and educator, renowned for his leadership in global health responses, including the Haiti earthquake, Ebola in Sierra Leone, and conflict zones in Ukraine. Serving as Chief Innovation Officer and Medical Director for Infectious Diseases at Access Health Louisiana, he delivers compelling lectures on HIV, HCV, STIs, and emerging epidemics. His professional presentations, such as at ACOI conferences and trauma training programs in Ukraine, integrate clinical expertise with actionable insights for healthcare providers. He harnesses media to combat infectious disease disinformation, including co-founding 102.3FM WHIV-LP community radio station in New Orleans 11 years ago to amplify human rights, social justice, and accurate health messaging.